Rivastigmine Tartrate NDC 55111-354

NDC codes

FDA NDC Directory

Product NDC (as listed)55111-354Labeler and product segments. Claims need a package NDC.

Product NDC at billing width55111-0354Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
55111-354-01	55111035401	100 CAPSULE in 1 BOTTLE (55111-354-01)Marketed from Sep 1, 2011
55111-354-05	55111035405	500 CAPSULE in 1 BOTTLE (55111-354-05)Marketed from Sep 1, 2011
55111-354-30	55111035430	30 CAPSULE in 1 BOTTLE (55111-354-30)Marketed from Sep 1, 2011
55111-354-60	55111035460	60 CAPSULE in 1 BOTTLE (55111-354-60)Marketed from Sep 1, 2011

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rivastigmine Tartrate
Generic name (nonproprietary): rivastigmine tartrate
Active ingredients: Rivastigmine tartrate — 4.5 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Dr. Reddy's Laboratories Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077130
Marketing start: Sep 1, 2011
Listing expires: Dec 31, 2026
Other FDA classes: Cholinesterase Inhibitors (Mechanism)
Identifiers: Product ID 55111-354_b6b13871-d413-7582-bd37-090b800d61f0SPL ID b6b13871-d413-7582-bd37-090b800d61f0SPL set ID 0e20124c-725a-0145-996c-2ff908703162RxCUI 312835, 312836, 314214, 314215UNII 9IY2357JPE
Pharmacologic class: Cholinesterase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N455111035401 followed by a unit qualifier and the quantity

Package 55111-0354-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 23, 2019.

Indications (excerpt from the label)

Rivastigmine tartrate capsule is an acetylcholinesterase inhibitor indicated for treatment of: Mild-to-moderate dementia of the Alzheimer’s type (AD) (1.1) Mild-to-moderate dementia associated with Parkinson’s disease (PD) (1.2) 1.1 Alzheimer’s Disease Rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type (AD). 1.2 Parkinson’s Disease Dementia Rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PD).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 077130

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 077130
Product	Strength	Form · route	Labeler	Product NDC
Rivastigmine Tartrate	Rivastigmine tartrate 1.5 mg/1	CapsuleOral	Dr. Reddy's Laboratories Limited	55111-352
Rivastigmine Tartrate	Rivastigmine tartrate 3 mg/1	CapsuleOral	Dr. Reddy's Laboratories Limited	55111-353
Rivastigmine Tartrate	Rivastigmine tartrate 6 mg/1	CapsuleOral	Dr. Reddy's Laboratories Limited	55111-355
Rivastigmine Tartrate	Rivastigmine tartrate 1.5 mg/1	CapsuleOral	American Health Packaging	60687-777